ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback